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Abstract 
 
Background: The potential of chemotherapy as salvage treatment after failure of neoadjuvant 
chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We 
conducted a single-centre, retrospective analysis to address this question. 
Patients and methods: Patients with newly diagnosed LARC who were inoperable or candidates 
for extensive (i.e., beyond total mesorectal excision, TME) surgery after long-course 
(chemo)radiotherapy and received salvage chemotherapy were included. The primary objective was 
to estimate the proportion of patients who became suitable for TME after chemotherapy. 
Results: Forty-five patients were eligible (39 candidates for extensive surgery and 6 unresectable). 
Previous radiotherapy was given concurrently with chemotherapy in 43 cases (median dose: 54.0 
Gy). Oxaliplatin- and irinotecan-based salvage chemotherapy was administered in 40 (88.9%) and 5 
(11.1%) cases, respectively. Eight patients (17.8%) became suitable for TME after chemotherapy, 
10 (22.2%) ultimately underwent TME with clear margins and 2 (4.4%) were managed with a 
“watch & wait” approach. Additionally, 13 patients had extensive surgery with curative intent. 3- 
year progression-free survival and 5-year overall survival in the entire population were 30.0% (95% 
CI: 15.0-46.0) and 44.0% (95% CI: 26.0-61.0), respectively. For the curatively resected and “watch 
& wait” patients these figures were 52.0% (95% CI: 27.0-73.0) and 67.0% (95% CI: 40.0-84.0), 
respectively. 
Conclusion: Systemic chemotherapy may be an effective salvage strategy for LARC patients who 
fail to respond to chemoradiotherapy and are inoperable or candidates for beyond-TME surgery. 
According to our study, 1 out of 5 patients may become resectable or being spared from an 
extensive surgery after systemic chemotherapy. 
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Implications for practice 
 
High-quality evidence to inform the optimal management of rectal cancer patients who are 
inoperable or candidates for beyond-TME surgery following standard chemoradiotherapy is 
lacking. We show for the first time that systemic chemotherapy may be beneficial and result in 1 
out of 5 poor prognosis patients becoming resectable or being spared from an extensive surgical 
approach. Although mores studies are needed to confirm these data, administering salvage systemic 
chemotherapy in this setting may have the potential to minimise morbidity associated with 
extensive surgical procedures and improve long-term oncological outcome. 
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Introduction 
 
Surgical resection according to the principles of total mesorectal excision (TME) is the mainstay of 
treatment for localised primary rectal cancer
1
. Routine adoption of TME and quality control of the 
resection specimens have led to a significant reduction of local recurrences and improvement of 
survival [1, 2]. Pre-operative short-course radiotherapy or long-course chemoradiotherapy have 
further improved complete excision and local recurrence rates but the impact of these treatments on 
long-term outcome of patients with resectable tumours is controversial [3, 4]. 
 
 
Over the last decade, the term locally advanced rectal cancer (LARC) has been increasingly used 
mostly as a result of the continuous efforts to implement risk-adapted treatment strategies. While 
there has not been consensus on the exact definition of LARC, it is clear that this entity includes a 
spectrum of heterogeneous cancers at one end of which are tumours that require extensive surgical 
approaches (i.e., beyond the TME planes or exenterative-type procedures) to achieve clear margins 
and unresectable tumours [5, 6]. Residual cancer within a distance of ≤1 mm from the 
circumferential resection margin (CRM) and involvement of adjacent organs (i.e., T4b) have been 
reported in approximately 1-33% and 10% of rectal cancers patients, respectively [7, 8]. These 
high-risk tumours can be reliably identified at baseline by high-resolution magnetic resonance 
imaging (MRI) [9] and patients are routinely treated with long-course chemoradiotherapy with the 
aim to not only reduce the risk of local recurrence but also downstage/downsize the tumour and 
allow a standard TME procedure with >1 mm clearance of tumour to the radial margins. 
 
It has been reported, however, that among patients with tumour involvement of the mesorectal 
fascia at baseline, 20% and 8% still have a predicted (i.e., imaging-based) CRM involvement and a 
positive pathological CRM after chemoradiotherapy, respectively [10]. Similarly, among patients 
who undergo chemoradiotherapy for tumours that are unresectable at diagnosis, 8% will remain 
inoperable   and   28%   will   require   an   exenterative-type   resection   [11].   Poor   response   to 
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chemoradiotherapy in these patients may have important clinical implications. A positive CRM is 
unanimously considered as one of the most powerful prognostic factors in rectal cancer due to its 
association with increased risk of both local and distant recurrence, and poor survival especially 
after administration of pre-operative radiotherapy [8]. Also, while exenterative-type surgical 
procedures can still achieve clear margins and compensate for inadequate tumour 
downstaging/downsizing after neoadjuvant therapy, these are likely burdened with higher rates of 
post-operative morbidity and mortality as well as deterioration of quality of life compared with 
standard TME [12, 13]. If, despite such extensive surgery, these patients succumb to distant 
metastatic disease (that now largely exceeds local recurrence as the main cause of death from rectal 
cancer) then the negative impact on quality of life may not be justified. 
 
 
Current international guidelines suggest that radiotherapy dose escalation (i.e., additional 10-20 Gy 
beyond conventional dose), intraoperative radiotherapy (IORT) or brachytherapy could be 
considered for patients with close/positive margins, T4 or unresectable tumours after standard 
neoadjuvant therapy [14]. However, data to support these approaches are scarce and there is 
uncertainty regarding their efficacy [15-18]. Notably, although mechanisms of radio- and chemo- 
resistance may differ and full dose systemic chemotherapy may provide a non-cross resistant 
treatment to deliver after failure of chemoradiotherapy, the use of this strategy in this setting has 
never been investigated [19]. 
 
 
In this article we report the results of a single institution, retrospective study that was designed to 
assess the impact of salvage systemic chemotherapy on the surgical approach and outcome of high- 
risk LARC patients who are still inoperable or candidates for extensive surgical procedures despite 
the use of standard long-course (chemo)radiotherapy. 
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Methods 
 
All patients who were last seen in consultation at the Royal Marsden NHS Foundation Trust 
between April 2004 and July 2015 following a diagnosis of rectal cancer were reviewed and 
checked against the following study inclusion criteria: 1) histological confirmation of 
adenocarcinoma; 2) distal edge of the luminal tumour within 15 cm of the anal verge as assessed by 
baseline MRI; 3) newly diagnosed tumours (i.e., recurrent tumours excluded); 4) no evidence of 
distant metastases at diagnosis; 5) tumour deemed to be unresectable or requiring extensive surgery 
(i.e., beyond the TME planes) following completion of neoadjuvant long-course 
(chemo)radiotherapy and restaging MRI as per treating surgeon/multidisciplinary team (MDT) 
assessment; 6) systemic chemotherapy administered as salvage treatment after long-course 
(chemo)radiotherapy with the intent to enable an R0 resection within the TME planes; 7) full 
medical records available for data extraction. 
 
 
According to the common practice at our institution over the study period, eligible patients 
underwent an MRI of the pelvis and a CT scan of the thorax, abdomen and pelvis at baseline for the 
purpose of tumour staging. The same scans were repeated after completion of neoadjuvant 
chemoradiotherapy and every 3 months during administration of salvage systemic chemotherapy. 
At each time point, these were prospectively reviewed at weekly institutional MDT meetings 
(involving gastrointestinal radiologists, medical oncologists, radiation oncologists, colorectal 
surgeons, and pathologists) where tumour resectability was assessed and a recommendation was 
made regarding the next management plan. In particular, MRI reassessment included evaluation of 
tumour regression grade (mrTRG), depth of extramural spread for tumour/fibrosis and relationship 
in mm of tumour to the TME plane. For patients requiring exenterative surgery the MRI assessment 
also included documentation of the compartments/organs involved by tumour [20]. 
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Generally, radiotherapy was conformally computed tomography planned and delivered by a two- 
phase technique (i.e., Phase 1 = 45 Gy in 25 fractions to the primary tumour and pelvic lymph 
nodes; Phase 2 = 5.4 in 3 fractions or 9 Gy in 5 fractions to the assessable tumour with a 2-cm 
margin in all directions). Following the MDT recommendation to consider salvage systemic 
treatment, the selection of the chemotherapy regimen was left to the discretion of the treating 
oncologist who decided based on a number of cinical parameters including age, performance status 
and comorbidities. For patients who underwent curative surgical resection follow-up included 
outpatient visits every 3 months for the first year, every 6 months for years 2 and 3 and every year 
for years 4 and 5. A CT scan of the thorax, abdomen and pelvis was done yearly for the first 3 years 
(MRI of the pelvis was performed as required). Carcinoembryonic antigen (CEA) test was repeated 
at each visit. Follow-up colonoscopies were performed within 12 months of surgery and, in the 
absence of significant findings, every 3 years thereafter. 
 
 
Data on demographics, clinico-pathological characteristics at baseline, neoadjuvant treatments, 
imaging at baseline, after (chemo)radiotherapy and after salvage systemic chemotherapy, pathology 
from resection specimens, adjuvant treatments, disease and survival status at the time  of  the 
analysis were retrospectively collected for each patient using the institutional electronic patient 
record system and entered into a database. Also, predicted type of surgery required based on 
imaging performed after completion of (chemo)radiotherapy and after systemic chemotherapy and 
type of surgery actually performed were annotated by reviewing the MDT recommendations (or 
surgical consultations if final decision was made at a later stage by the treating surgeon) and the 
operation notes, respectively. Pelvic MRI scans were retrospectively reviewed by a specialised 
gastrointestinal radiologist (GB) for the purpose of assessing some imaging parameters whenever 
corresponding data could not be extrapolated from the original radiology report. 
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The primary objective of the study was to assess the proportion of patients who were deemed to be 
unresectable or candidates for extensive surgery after (chemo)radiotherapy and became suitable 
(based on pre-operative imaging) for TME after salvage systemic chemotherapy. Secondary 
objectives included the proportion of patients who underwent TME surgery, rate of R0 resection, 
response to salvage systemic chemotherapy as assessed by imaging-based parameters [including T 
downstaging, N downstaging, 30% reduction of intraluminal cranio-caudal tumour length, change 
of extramural venous invasion (EMVI) status, change of CRM status, MRI tumour regression grade 
(mrTRG)], progression-free survival (PFS) and overall survival (OS) in the overall study population 
and in the curatively resected (i.e., R0 or R1 resection) population, and pattern of treatment failure. 
 
 
T and N downstaging were defined as reduction of at least 1 level in T and N staging, respectively, 
between baseline MRI and post-treatment MRI or histopathological staging. mrTRG was defined as 
previously reported [21]. In brief, mrTRG 1 indicated radiological complete response (i.e., no 
evidence of residual tumour signal), mrTRG 2 good response (i.e., predominant fibrosis signal 
intensity with minimal residual tumor), mrTRG 3 moderate response (i.e., mixed areas of low signal 
fibrosis and intermediate signal intensity), mrTRG 4 minor response (i.e., persistent intermediate 
signal intensity with minimal low signal fibrosis) and mrTRG 5 no response (i.e., intermediate 
signal intensity, same appearances as original tumour). All survival outcomes were calculated from 
the start of salvage systemic chemotherapy. PFS was defined as time from start of systemic 
chemotherapy to date of progression (or unresectable disease based on either pre-operative imaging 
or intraoperative findings for those patients who did not undergo curative surgery) or death from 
any cause. OS was defined as time from start of systemic chemotherapy to date of death from any 
cause. Alive patients were censored at date of last follow-up. Both PFS and OS were analysed using 
the Kaplan-Meier method. 
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The study was approved by the Research & Development Department at the Royal Marsden NHS 
Foundation Trust. Due to the retrospective nature of the analysis, consent from patients included in 
the study was not required. 
 
 
Results 
 
A total of 45 patients who were diagnosed between December 2001 and May 2015 met the study 
inclusion criteria. The majority of these (n=38, 84.4%) were diagnosed after January 2010. Patient 
demographics and characteristics at baseline are shown in Table 1. There was a predominance of 
males (73.3%) and median age was 59 [interquartile range (IQR): 51.9 – 72.0]. All patients had ≥T3 
tumours and the vast majority of them had mid or low rectal cancers (80.0%), N2 disease (73.4%), 
EMVI (86.7%), and predicted CRM involvement (93.4%). Poorly differentiated and mucinous 
tumours (based on either histology from the diagnostic biopsy or staging MRI) were found in 
13.3% and 20.0% of cases, respectively. 
 
 
All patients received upfront fractionated pelvic radiotherapy. Median dose of radiotherapy was 
 
54.0 Gy (IQR: 54.0 – 54.0; range: 34.0 – 55.8) and median duration of treatment was 42 days (IQR: 
 
41.0 – 43.0; range: 13.0 – 57.0). In all cases, with the exception of two patients, radiotherapy was 
given concurrently with chemotherapy. This mostly consisted of single agent capecitabine (n=41, 
95.3%). One patient received a combination of fluorouracil and oxaliplatin while in one other case 
capecitabine was replaced by raltitrexed due to pre-existing patient cardiovascular comorbidities. 
Median time from the completion of radiotherapy to the restaging pelvic MRI scan was 31 days 
(IQR: 28.0 – 35.0; range: 21.0 – 80.0). Details of tumour characteristics after (chemo)radiotherapy 
and response to treatment are reported in Table 1 and 2, respectively. After MDT discussion and/or 
surgical consultation, 39 patients (86.7%) were deemed to be candidates for beyond TME surgery 
while 6 (13.3%) were considered inoperable (in 3 cases tumour unresectability was confirmed 
during explorative surgery). 
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Systemic treatment after (chemo)radiotherapy is presented in Table 3. Doublet chemotherapy plus 
or minus bevacizumab was given to 44 patients (97.8%). In most cases patients received an 
oxaliplatin-based regimen (n=40, 88.9%) while an irinotecan-based regimen was used in 5 cases 
(11.1%, including one patients who started with single agent capecitabine and was subsequently 
switched to FOLFIRI). Treatment was administered for a median of 3.3 months (IQR: 2.4 – 5.3; 
range: 1.1 – 8.2) and in 16 patients (35.6%) this was continued beyond the first radiological 
assessment. Median time from treatment start to the first restaging pelvic MRI and pre-operative 
pelvic MRI was 2.6 months (IQR: 2.4 – 3.1; range: 1.6 – 7.0) and 3.3 months (IQR: 2.5 – 5.4; 
range: 1.6 – 10.3), respectively. Details of tumour characteristics after salvage chemotherapy and 
incremental response to treatment (as compared to the post-radiotherapy findings) are reported in 
Table 1 and 2. Eight patients (17.8%) were diagnosed with distant metastases during or after 
completion of chemotherapy. Among the remaining 37 patients, the MDT and/or treating surgeon 
considered 29 (64.4%) as still either inoperable (including 1 patient who became unresectable due 
to local progression while on chemotherapy) or candidates for beyond TME surgery while 8 
(17.8%) were deemed suitable for a TME approach. The latter group included 2 patients with 
unresectable tumours at baseline (as confirmed during explorative surgery) and 2 other patients who 
continued with the same chemotherapy despite the first MRI assessment after 3 months of treatment 
suggested that an extensive surgery would be still required (Figure 1). Median time from start of 
systemic chemotherapy to first MRI showing that a TME was technically feasible was 5.3 months 
(IQR: 3.5 – 7.6; range: 3.0 – 8.5). 
 
A total of 23 patients (51.1%) underwent surgery with a curative intent (1 additional patient had an 
R2 palliative surgery which was required due to severe anal pain and MRI evidence of rectal 
perforation after chemotherapy). An extensive resection was undertaken in 13 cases while 10 
patients   were   ultimately   amenable   to   TME   surgery   (i.e.,   5   anterior   resections   and   5 
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abdominoperineal resections) including 4 who were deemed to be candidates for a beyond TME 
surgery according to the MDT and/or treating surgeon (Figure 1). In these 4 cases, the interval 
between MRI after salvage chemotherapy and surgery was 30, 45, 87 and 91 days, respectively. An 
R0 resection (i.e., pathological CRM clear) was achieved in 21 cases, including all patients who 
underwent TME. A pathological complete response was observed in 3 patients (1 in the extensive 
surgery group and 2 in the TME group) (Table 4). Reasons why surgery was not performed 
included: distant metastases (n=8), unresectable primary tumour (n=4, in 1 case tumour became 
unresectable due to local progression while awaiting patient decision regarding exenterative 
surgery), risk/benefit ratio of an exenterative procedure felt unacceptable  by patient/physician 
(n=6), loss to follow-up (n=1). Two additional patients were proposed a “watch and wait” approach 
following radiological evidence of complete or almost complete tumour response. Post-operative 
adjuvant chemotherapy was administered in 7 patients (including 1 patient who also had cyberknife 
treatment due to a positive margin). 
 
 
After a median follow-up of 38.7 months (IQR: 24.7 – 43.1), in the overall study population 3-year 
PFS was 30.0% (95% CI: 15.0 – 46.0) and 5-year OS was 44.0% (95% CI: 26.0 – 61.0). In the 
macroscopically radically resected and “watch and wait” population (n=25), these figures were 
52.0% (95% CI: 27.0 – 73.0) and 67.0% (95% CI: 40.0 – 84.0), respectively (median follow-up for 
this patient population: 44.7 months (IQR: 14.2 – not reached) (Figure 2). At the time of this 
analysis, among patients who had curative resection, tumour recurrence was diagnosed in 10 cases 
(local recurrence alone in 2, local and distant recurrence in 1, and distant recurrence alone in 7). 
The two patients who were managed with “watch and wait” were alive and free of disease after 19.7 
and 24.6 months from start of salvage chemotherapy. 
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Discussion 
 
In this study we have shown that administering systemic chemotherapy after poor response to 
neoadjuvant chemoradiotherapy may be an effective salvage strategy to allow a TME with clear 
surgical margins in some LARC patients who would otherwise be inoperable or candidates for an 
extensive surgery. 
 
 
Over the last few years, an interest in the use of systemic chemotherapy in the pre-operative setting 
has increasingly emerged. A number of strategies have been investigated including induction 
chemotherapy before chemoradiotherapy [22], systemic chemotherapy (without radiotherapy) 
followed by surgery [23], and consolidation chemotherapy after chemoradiotherapy [24], all with 
encouraging results. Nevertheless, to our knowledge, the potential of chemotherapy as a salvage 
treatment for patients who achieve suboptimal response to chemoradiotherapy has never been 
explored. 
 
 
Our series included a selected group of poor-prognosis LARC patients as shown by the high 
proportion of tumours with prognostically unfavourable imaging characteristics at baseline (i.e., 
advanced TN stage, presence of EMVI and predicted CRM involvement) and the lack of substantial 
downstaging/regression after long-course (chemo)radiotherapy. More importantly, despite the use 
of standard neoadjuvant therapy, all patients were candidates for either an aggressive surgical 
approach (i.e., beyond the conventional TME planes) or a palliative treatment due to the local 
extent of their tumours. Further confirmation of the poor prognosis of our study population is 
provided by the modest long-term survival outcomes including a 3-year PFS of 30.0% and a 5-year 
OS of 42.8% which lag far behind the corresponding historical figures for unselected LARC 
patients who are treated with neoadjuvant chemoradiotherapy [25]. 
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The findings of our study suggest that 1 out of 5 such high-risk LARC patients can have their 
tumour resected or be spared from the consequences of an extensive surgery following the use of 
sequential systemic chemotherapy. Notably, all patients who underwent TME had negative surgical 
margin (i.e., R0 resection) and in two cases a pathological complete response was also observed. 
Moreover, two additional patients had the opportunity to avoid surgery and undergo a “watch and 
wait” approach due to the radiologic evidence of a clinical complete response at the end of 
chemotherapy. Although the absence of an appropriate control group and the unavailability of 
patient reported outcome data do not allow us to draw any definitive conclusion, it is likely that the 
change of surgical approach resulting from the administration of salvage systemic chemotherapy 
might have minimised the risk of tumour- and treatment-related morbidities and translated into 
better quality of life and improved survival. 
 
 
Delay of surgery and increased risk of tumour progression is one of the main concerns around the 
administration of chemotherapy in patients who are still amenable to an extensive resection after 
completion of standard chemoradiotherapy. In our study, however, local tumour progression 
precluding curative resection after salvage chemotherapy occurred only in 1 out of 39 potentially 
resectable patients (2.6%). Although a further 18% were diagnosed with distant metastases while on 
or soon after completion of chemotherapy, it is unlikely that these patients might have missed the 
chance of a potentially curative surgical resection. These patients are known to be at high risk of 
distant failure and lack of response to chemoradiotherapy is a further high-risk feature. Stretching 
the interval from chemoradiotherapy to surgery by administering sequential chemotherapy could 
actually provide an opportunity window to identify poor prognosis patients with rapidly progressing 
tumours and restrict exenterative-type surgical resections to those who are most likely to benefit. 
 
While the overall impact of systemic chemotherapy in this setting may appear promising (i.e., 
change of treatment approach in 26.7% of cases) it is possible that there is scope for yet further 
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improvement. Virtually all study patients were treated with oxaliplatin- or irinotecan-based doublet 
chemotherapy whereas only a minority (6.7%) also received bevacizumab. It is legitimate to 
hypothesise that more aggressive regimens including doublet chemotherapy plus either anti- 
angiogenic agents or anti-EGFR monoclonal antibodies and triplet chemotherapy (plus or minus 
biologics) could lead to higher tumour regression rates and increase the proportion of patients who 
become candidates for a TME surgery despite poor response to chemoradiotherapy [26-30]. We 
have previously demonstrated that adding cetuximab to neoadjuvant doublet chemotherapy (i.e., 
before chemoradiotherapy) significantly improves the objective response rate in locally advanced 
rectal patients with RAS wild-type tumours [31, 32]. Furthermore, overexpression of EGFR has 
been reported to be a predictive factor of resistance to radiotherapy in rectal cancer and using anti- 
EGFR agents after failure of chemoradiotherapy may represent a rational strategy to target 
biologically aggressive tumour clones [33-37]. 
 
 
While some patients had a significant benefit in terms of surgical approach from the use of salvage 
chemotherapy, the majority of them (73.3%) were still deemed as inoperable or candidates for an 
extensive surgical procedure. One could argue that these patients may have received an unnecessary 
treatment which, in addition to the abovementioned risk of tumour progression, could also be 
associated with increased toxicities and possibly detriment of quality of life. The design of our 
study does not allow us to estimate the benefit (if any) of salvage chemotherapy in this group of 
patients. However, we have shown that administering systemic chemotherapy after 
chemoradiotherapy led to some incremental tumour response (as indicated by a number of imaging- 
based parameters) which, regardless of the type of surgical resection performed (i.e., TME or 
beyond-TME), may have ultimately translated into improved outcome. Also, it should be noted that, 
in view of the high-risk features of their tumours, these patients would be very likely to be proposed 
the  same  treatment  after  surgery,  a  setting  where  the  efficacy of  chemotherapy is  yet  to  be 
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demonstrated and the risk of toxicity and low compliance appears significantly higher compared 
with pre-operative chemotherapy [38, 39]. 
 
 
Our analysis has a number of limitations in addition to the small sample size and the retrospective 
design. The definition of tumour resectability in this study was based on MR imaging that has been 
previously reported to be as effective as pathology at predicting the likelihood of local recurrence, 
disease-free survival and overall survival [40]. Furthermore mrTRG has also been validated as a 
method of predicting response to treatment [21, 41]. However, especially when non high-resolution 
techniques are employed and MERCURY-defined criteria are not used, MRI is less specific in the 
assessment of parameters such as involvement of the mesorectal fascia after administration of 
neoadjuvant chemoradiotherapy [42, 43]. Nevertheless, it is unlikely that this may have led to an 
excess of patients who were considered to be inoperable or candidates for extensive surgical 
approaches after standard chemoradiotherapy and became suitable for TME after chemotherapy. In 
our study 4 out of 26 patients (15%) who were deemed to be candidates for a beyond-TME surgical 
approach after salvage chemotherapy ultimately underwent TME. While imaging cannot 
confidently rule out residual microscopic foci of cancer within the dense fibrotic tissue 
threatening/involving the mesorectal fascia, the discrepancy between type of surgery that was 
recommended after completion of salvage chemotherapy and that which was actually carried out is 
more likely to reflect the willingness of some surgeons to cut through fibrotic tissue to allow a 
sphincter-preserving surgery rather than an overall poor accuracy of MRI as such. This also reflects 
the learning curve of our MDT in relation to the management of patients with locally advanced 
tumours who are likely candidates for a beyond-TME surgical approach. Moreover, the relatively 
long interval between MRI assessment after salvage chemotherapy and surgery may have accounted 
for at least some of the observed discrepancies. The contention that the results of our study are not 
significantly biased by the decision to rely on MRI for the assessment of tumour resectability and 
definition of surgical plan is supported by the fact that 2 out of 10 patients who underwent TME 
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following chemotherapy were truly inoperable as reported by the treating surgeon during 
exploratory surgery after completion of chemoradiotherapy. 
 
 
Another potential limitation is the median time interval from completion of chemoradiotherapy to 
tumour assessment which in our study was lower (i.e., 4.4 weeks) compared with what is now 
considered as the optimal standard by international guidelines and consensus statements on LARC 
beyond TME planes (i.e., 6-8 weeks) [6, 14, 44]. Therefore, it cannot be excluded that some of the 
downstaging/downsizing effects which have been attributed to salvage systemic chemotherapy may 
actually be secondary to delayed radiotherapy-induced tumour regression [45, 46]. However, it is 
worth noting that in 2 cases tumour resectability according to the TME principles was achieved 
only after approximately 6 months of systemic chemotherapy, this being continued beyond the first 
MRI after 3 months of treatment showed that an extensive surgery was still required. This mitigates 
against a significant impact of possible confounding factors on the study results and further support 
a true “rescue effect” of salvage chemotherapy in this setting. Especially in this group of locally 
advanced tumours with no/minimal signs of tumour regression soon after completion of 
chemoradiotherapy, it is very unlikely that a substantial, chemoradiotherapy-induced, delayed 
tumour regression may have occurred and led to a change in surgical approach. Indeed, studies 
suggest that the highest benefit from neoadjuvant chemoradiotherapy (in terms of tumour 
downstaging, pathological complete response or radical resection) is observed from 8 to 11 weeks 
after completion of treatment [46, 47]. Delaying surgery beyond this timeframe may actually 
increase the risk of positive resection margins possibly as a result of tumour re-growth [47]. 
 
Main strengths of our analysis are the adoption of a well-defined, largely homogeneous 
management pathway for LARC patients for the duration of the study and the collection of 
prospectively annotated recommendations from institutional MDT meetings which were regularly 
attended  by  a  highly  experienced  team  of  clinicians  including  specialised  gastrointestinal 
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radiologists and colorectal surgeons. Also, although the overall study period spanned over 
approximately 15 years, the vast majority of patients were treated within the last 5 years, this 
reinforcing the contention that our findings are generalisable to the current clinical practice. This 
strategy is being tested in a prospective multicentre trial (TRIGGER) in which patients are 
randomised to an experimental arm of sequential systemic chemotherapy or deferral of surgery 
based on mrTRG after chemoradiotherapy (NCT02704520) [48]. 
 
 
In conclusion, our retrospective analysis suggests that systemic chemotherapy could be a useful 
salvage strategy for high-risk LARC patients who are still inoperable or require extensive surgical 
procedures after standard chemoradiotherapy. While administering chemotherapy in this setting 
may already be a relatively common practice in some centres, this has been largely empirical and 
not supported by any evidence. Herein we provide for the first time a valuable source of 
information on the potential of salvage chemotherapy that can be used in the decision-making 
process whenever the prospect of an exenterative-type resection or palliative treatment is envisaged 
after failure of standard neoadjuvant therapy. Prospective studies are certainly required to confirm 
our data and possibly assess the role of systemic chemotherapy in this setting against alternative 
therapeutic options. 
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BEST PRACTICE 
 
 
CURRENT PRACTICE 
 
 
RESULTING GAPS 
 
 
LEARNING 
OBJECTIVES 
 
 
 
 
 
 
Treatment 
recommendations and 
clinical decisions should 
ideally be based on high- 
quality evidence (i.e., 
prospective clinical 
trials). 
 
When this is lacking, 
retrospective studies are 
valuable tools to inform 
routine practice and 
partially fill the 
knowledge gaps. 
 
 
 
There is currently no 
consensus on the optimal 
management of LARC 
patients who remain 
inoperable or candidate 
for beyond-TME surgery 
following standard 
neoadjuvant 
chemoradiotherapy. 
 
Potential treatment 
approaches include 
radiotherapy dose 
escalation, intraoperative 
radiotherapy or 
brachytherapy. However, 
data to support these 
salvage treatments are 
scarce and there is 
uncertainty regarding 
their efficacy. 
 
 
 
 
 
The management of 
chemoradiotherapy 
refractory LARC is 
largely empirical and the 
prognosis of these 
patients remains poor. 
 
No study has ever 
addressed the role of 
systemic chemotherapy 
as salvage treatment 
option in this setting. 
 
To consider the lack of 
high-quality evidence for 
the management of 
LARC patients who 
remain inoperable or 
candidate for extensive 
surgical procedures 
following neoadjuvant 
chemoradiotherapy. 
 
To obtain valuable 
information on the 
potential of systemic 
chemotherapy as salvage 
treatment after failure of 
standard neoadjuvant 
chemoradiotherapy. 
 
To recognise 
chemoradiotherapy 
refractory LARC as an 
area of unmet need and 
prioritise research in this 
setting. 
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Table 1. Demographics and patient characteristics at baseline, after neoadjuvant 
(chemo)radiotherapy and after salvage systemic chemotherapy 
 
  
Baseline (%) 
 
After (C)RT (%) 
 
After CT (%) 
Gender 
male 
female 
 
33 (73.3) 
12 (26.7) 
 
- 
- 
 
- 
- 
Median age (IQR) 59 (51.9 – 72.0) - - 
Tumour site 
 
9 (20.0) 
 
- 
 
- high rectum 
mid rectum 16 (35.6) - - 
low rectum 20 (44.4) - - 
Grade 
 
33 (73.4) 
 
- 
 
- well/mod diff 
poorly diff 6 (13.3) - - 
missing 6 (13.3) - - 
Mucinous
*
 
 
9 (20.0) 
 
- 
 
- yes 
no 36 (80.0) - - 
T stage 
 
0 (0) 
 
0 (0) 
 
2 (4.4) 2 
3 32 (71.1) 26 (57.8) 22 (49.0) 
4 13 (28.9) 19 (42.2) 19 (42.2) 
missing 0 (0) 0 (0) 2 (4.4) 
Median cranio-caudal 
lenght
** 
(mm) (IQR) 
60.0 (50.0 – 78.0) 44.0 (35.0 – 60.0) 38.0 (27.0 – 48.5) 
N stage 
 
2 (4.4) 
 
12 (26.7) 
 
22 (48.9) 0 
1 9 (20.0) 20 (44.4) 13 (28.9) 
2 33 (73.4) 13 (28.9) 7 (15.6) 
missing 1 (2.2) 0 (0) 3 (6.6) 
Pelvic sidewall nodes 
 
27 (60.0) 
 
34 (75.6) 
 
38 (84.4) no 
yes 16 (35.6) 10 (22.2) 3 (6.7) 
missing 2 (4.4) 1 (2.2) 4 (8.9) 
EMVI 
 
4 (8.9) 
 
2 (4.4) 
 
13 (28.9) no 
yes 39 (86.7) 41 (91.2) 28 (62.2) 
missing 2 (4.4) 2 (4.4) 4 (8.9) 
MRF involved/at risk 
 
2 (4.4) 
 
2 (4.4) 
 
9 (20.0) no 
yes 42 (93.4) 43 (95.6) 34 (75.6) 
missing 1 (2.2) 0 (0) 2 (4.4) 
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mrTRG 
 
- 
 
0 (0) 
 
11 (24.4)  1-2 
 3 - 10 (22.2) 13 (28.9) 
 4-5 - 32 (71.1) 16 (35.6) 
 missing - 3 (6.7) 5 (11.1) 
 
* Based on either histology from the diagnostic biopsy or MRI at baseline 
** Data available for 43 patients 
 
 
 
Abbreviations: CRT: chemoradiotherapy; CT: chemotherapy; IQR: interquartile range; mod diff: moderately differentiated; poorly diff: poorly 
differentiated; EMVI: extramural venous invasion; MRF: mesorectal fascia; mrTRG: magnetic resonance imaging tumour regression grade; 
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Table  2.  Imaging-based  response  to  neoadjuvant  (chemo)radiotherapy  and  salvage  systemic 
chemotherapy 
 
 
 
Parameter of response 
 
After (C)RT (%) After CT (%)
*
 
 
T downstaging 
 
0/45 (0) 
 
3/36 (8.3) 
 
N downstaging 
 
24/42 (57.1) 
 
14/36 (38.9) 
 
≥30% reduction in cranio-caudal lenght 
 
16/42 (38.1) 
 
7/34 (20.6) 
 
Change in pelvic sidewall node status (i.e., pos neg) 
 
8/16 (50.0) 
 
5/8 (62.5) 
 
Change in EMVI status (i.e., pos neg) 
 
2/38 (5.3) 
 
12/35 (34.3) 
 
Change in predicted CRM status (i.e., pos neg) 
 
0/42 (0) 
 
7/34 (20.6) 
 
Further tumour regression (based on mrTRG) 
 
- 
 
20/34 (58.8) 
 
* 
Response to chemotherapy is assessed by using imaging data after completion of chemoradiotherapy as baseline and only in patients who did not 
experience distant progression while on treatment 
 
Abbreviations: CRT: chemoradiotherapy; CT: chemotherapy; EMVI: extramural venous invasion; MRF: mesorectal fascia; CRM: circumferential 
resection margin; mrTRG: magnetic resonance imaging tumour regression grade; pos: positive; neg: negative. 
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Table 3. Chemotherapy regimens used after (chemo)radiotherapy in the study population 
 
 
Chemotherapy regimen N % 
Oxaliplatin-based chemotherapy 40 88.9 
CAPOX (28) (62.2) 
FOLFOX (9) (20.0) 
FOLFOX-BEVACIZUMAB (2) (4.5) 
RALTITREXED-OXALIPLATIN (1) (2.2) 
 
Irinotecan-based chemotherapy 5 11.1 
FOLFIRI (2) (4.5) 
FOLFIRI- BEVACIZUMAB (1) (2.2) 
CAPIRI (1) (2.2) 
IRINOTECAN (1) (2.2) 
 
 
Abbreviations: CAPOX: capecitabine and oxaliplatin; FOLFOX: fluorouracil and oxaliplatin; FOLFIRI: fluorouracil and irinotecan; CAPIRI: 
capecitabine and irinotecan. 
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Table 4. Pathology findings from the resection specimens of patients who underwent surgery with a 
curative intent (n=23) 
 
Pathological characteristics N % 
ypTN stage (n=23) 
ypT0N0 3 13.0 
ypT0N1 1 4.4 
ypT2N0 5 21.7 
ypT3N0 9 39.1 
ypT3N1 2 8.8 
ypT4N0 3 13.0 
Number of lymph nodes retrieved 
Median (range) 8 (3 – 30) 
ypEMVI (n=23) 
No 20 87.0 
Yes 3 13.0 
Dworak regression grade (n=16) 
1 1 6.2 
2 7 43.8 
3 5 31.3 
4 3 18.7 
CRM involvement (≤1 mm) (n=23) 
No 21 91.3 
Yes 2 8.7 
 
Abbreviations: EMVI: extramural venous invasion; CRM: circumferential resection margin. 
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Figure legends 
 
 
 
 
Figure 1. Study flow diagram 
 
Footnote 
 
Reasons why surgery was not performed included: 
 
* 
Unresectable tumour (n=3) and extensive surgery declined by patient (n=1) 
** 
Distant metastases (n=8), risk/benefit ratio of an exenterative procedure felt unacceptable by patient/physician (n=6), 
unresectable tumour (n=1; tumour became unresectable  due to local progression while awaiting patient decision 
regarding exenterative surgery), loss to follow-up (n=1). 
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Figure 2. Kaplan-Meier curves for progression-free survival (a) and overall survival (b) in patients 
who underwent macroscopically radical resection (i.e., R0 or R1) or were managed with a “watch 
and wait” approach (n=25) 
